title: Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias.
abstract: Fungal infections are a major problem in patients with hematologic malignancy. Attempts to reduce their frequency with antifungal agents have not been successful. A double-blind, controlled, single-center trial was conducted with 96 consecutive patients undergoing 154 episodes of chemotherapy. Patients received 400 mg of fluconazole or placebo until bone marrow recovery or initiation of intravenous amphotericin B infusions. End points were amphotericin B use, fungal infection, stable neutrophil count > 0.5 x 10(9)/L, toxicity precluding further fluconazole use, and death. By Kaplan-Meier estimation, the time to initiation of amphotericin B therapy was shorter in 76 patients treated with placebo than in 75 treated with fluconazole (P = .003). Also, fluconazole reduced the number of febrile days by 20% (P = .002) and prevented oropharyngeal candidiasis (1/75 vs. 9/76, P = .018). The frequency of deep mycoses (8/76 vs. 8/75) and outcome were unaffected. Fluconazole did not have a favorable effect on infection-related health care costs and was associated with prolonged severe neutropenia (P = .01).
authors.affiliation: Department of Medicine, University Hospital, Zurich, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Schaffner
authors.forename: M
authors.initials: M
authors.lastname: Schaffner
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000191:economics; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000517:prevention & control; D016470:Bacteremia / Q000139:chemically induced; D002180:Candidiasis, Oral / Q000517:prevention & control; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005334:Fever / Q000517:prevention & control; D015725:Fluconazole / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D009503:Neutropenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole